NIVF vs ONCO
Valuation
Profitability
Growth
Financial Health
Dividends
AI Verdict
NIVF exhibits a catastrophic price collapse (-99.8% over 1 year) and severe operational dysfunction. While the Piotroski F-Score of 5/9 suggests baseline stability, this is heavily skewed by a non-operating profit spike, as evidenced by a 209.03% profit margin contrasted against a disastrous -349.13% operating margin. The company is fundamentally unable to generate profit from its core medical care facilities. The massive discrepancy between the current price ($2.19) and the single analyst's target price ($900) indicates a complete breakdown in valuation reliability.
ONCO exhibits critical financial distress, anchored by a Piotroski F-Score of 1/9, indicating severe fundamental weakness. The company is in a catastrophic price collapse, falling from a 52-week high of $74.38 to $0.76, representing a near-total loss of market value. With a current ratio of 0.66 and revenue plummeting by 57.40% YoY, the firm faces an immediate liquidity crisis and a failing business model. The combination of extreme operating losses (-422.06% margin) and a bearish technical trend suggests a high probability of insolvency.
Compare Another Pair
Related Comparisons
NIVF vs ONCO: Head-to-Head Comparison
This page compares NewGenIvf Group Limited (NIVF) and Onconetix, Inc. (ONCO) across key fundamental metrics including valuation ratios, profitability margins, growth rates, financial health indicators, and dividend metrics. Each metric highlights the better-performing stock so you can quickly identify relative strengths and weaknesses.
Our AI engine independently analyzes each company's financials, competitive position, and market conditions to produce a verdict (Bullish, Neutral, or Bearish) along with key strengths and risks. Use this comparison alongside your own research to make informed investment decisions.